Background and purpose: Apoptosis-inducing factor mitochondrion-associated-1 (AIFM1) in mitochondria has captured a great deal of attention due to its well-described function in apoptosis. Mutations in AIFM1 have resulted in multiple clinical phenotypes, including X-linked Charcot-Marie-Tooth disease type 4. These syndromes usually involve multiple locations within the nervous system and/or multiple organs. This study describes a novel missense mutation in AIFM1 and its associated peripheral nerve disease. Methods: Patients with AIFM1 mutation were characterized clinically, electrophysiologically, genetically and by magnetic resonance imaging. The fibroblasts were isolated from the patients to study mitochondrial OXPHOS complexes. Results: We identified a family with a novel missense mutation (Phe210Leu) in AIFM1 who developed an isolated late-onset axonal polyneuropathy in which the central nervous system and other organs were spared. Interestingly, this Phe210-Leu mutation resulted in abnormal assembly of mitochondrial complex I and III, and failed to disrupt AIFM1 binding with mitochondrial intermembrane space import and assembly protein 40 (MIA40) in the patients' cells. Deficiency of either AIFM1 or MIA40 is known to impair the assembly of mitochondrial complex I and IV. However, levels of both AIFM1 and MIA40 were unchanged. Conclusions: Phe210Leu mutation in AIFM1 induces an axonal polyneuropathy that might be contributed by the misassembly of mitochondrial complex I and III. This misassembly appears to be independent of the traditional mechanism via AIFM1/MIA40 deficiency.
Introduction
Charcot-Marie-Tooth disease (CMT) affects one in 2500 people. Most patients with CMT share many phenotypic features, including chronic sensory loss, muscle weakness and atrophy in distal limbs. Of 90 human genes associated with CMT, four genes are mapped to chromosome X, including apoptosis-inducing factor mitochondrion-associated-1 (AIFM1) at Xq26.1. Mutations in AIFM1 cause axonal polyneuropathy in patients with X-linked CMT type 4 [1] .
AIFM1 encodes a 67-kDa flavin adenine dinucleotidedependent nicotinamide adenine dinucleotide oxidase with a mitochondrial-specific targeting sequence (mitochondrial localization signal) of 54 amino acids at its N-terminal. The remaining protein consists of the inner membrane sorting signal domain (55-128), two flavin adenine dinucleotide domains (129-262, 401-480), a nicotinamide adenine dinucleotide-binding domain (263-400) and a C-terminal domain (481-608) (Fig. 1a) . In response to apoptotic stimuli, AIFM1 cleaves off its N-terminal at residue 101 to become cytosolic AIFM1 and translocates into the nucleus resulting in DNA fragmentation and cell death [2] . Heat-shock protein-70 binds AIFM1 at residues 150-288 in the cytosol, preventing nuclear translocation and thus inhibiting apoptosis [3] .
Mitochondria execute their essential function, i.e. energy production, through the oxidative phosphorylation system (OXPHOS). OXPHOS is comprised of five protein complexes (CI-CV) in the inner mitochondrial membrane. OXPHOS couples the electron flow and proton translocation across the mitochondrial inner membrane to generate the electrochemical gradient that enables the production of ATP. In both cultured cells and mouse tissues, AIFM1 has been shown to interact with MIA40 (an oxidoreductase). Partial deficiency of AIFM1 (~80%) resulted in loss of MIA40 and misassembly of CI and CIV leading to muscle atrophy, astrogliosis and progressive neurodegeneration in a mouse model [4] .
In addition, mutations in human AIFM1 have been associated with a wide spectrum of clinical phenotypes, including X-linked CMT type 4 (Table 1 ; Fig. 1a ). In the vast majority of cases with AIFM1 mutation, patients develop abnormalities in the central nervous system and/or other organs in addition to axonal polyneuropathy. However, in this study we report a family carrying a novel missense mutation in AIFM1 that exhibits an isolated axonal polyneuropathy with misassembly of CI and CIII.
Materials and methods

Patients
The affected proband (0001) was initially evaluated at the Vanderbilt CMT Clinic. The proband, his affected brother (0100) and his unaffected sister (0102) were then evaluated at the Clinical Research Center of Vanderbilt University Medical Center (Fig. 1b) . This study was approved by the local Institutional Review Board. Written consent was obtained from all participants. The proband's unaffected brother (0103) and his asymptomatic sister (0101) were consented and interviewed over the phone.
In addition to medical history and neurological examination, the CMT neuropathy score [5] was obtained from patients 0001, 0100 and 0102. The electrophysiological portion of the score was omitted to produce the CMT Examination Score (CMTES). The electrophysiological data will be described separately. CMTES ranges from 0 to 28, with higher scores indicating an increase of disease severity.
Nerve conduction studies
Nerve conduction studies (NCS) data were acquired using conventional methods [6] .
DNA sequencing
Next-generation sequencing The proband's DNA was initially evaluated by targeted gene-panel next-generation sequencing, a service Figure 1 (a) Functional domains and published pathogenic mutations in apoptosis-inducing factor mitochondrionassociated-1 (AIFM1). Shown are the mitochondrial localization signal (MLS), inner membrane sorting signal (IMSS), flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide (NADH) and C-terminal domains in AIFM1. (b) Family pedigree and lengthdependent muscle atrophy in the proband (?). Medical history and DNA were collected from subjects marked with numerical codes. Participants 0001, 0100 and 0102 were also examined clinically and electrophysiologically. Medical history and physical examination were not available for members labelled with a question mark. □, male; ○, female; ■ clinically affected; , carrier but clinically unaffected by polyneuropathy; diagonal line, deceased; NT, not tested. (c) Severe muscle atrophy was seen in distal legs. However, the muscle bulk was well preserved in hands and arms.
provided by Medical Neurogenetics (Atlanta, GA, USA). The test sequenced 42 CMT-related genes and mitochondrial DNA as described previously [6] .
Sanger sequencing
Primers (5 0 -TCTGGACACTGGCAAACATC-3 0 and 5 0 -GCTTTCCCCAGAAAGACACA-3 0 ) were used to amplify a 491-bp region of AIFM1. Polymerase chain reaction products were then sequenced by GenHunter Corporation (Nashville, TN, USA).
Human skin biopsy and fibroblast culture Skin biopsies (2 mm in diameter) were obtained from the forearms of the proband (0001), his brother (0100) and his sister (0102). Fibroblasts were cultured from the biopsies as described previously [6] and harvested for biochemical studies.
Western blot and co-immunoprecipitation
This method was modified from our previously published study [6] . In brief, human fibroblast cells were lysed in immunoprecipitation buffer (cat. no. 87788; Thermo Scientific, Asheville, NC, USA) and incubated with primary antibodies overnight at 4°C. Protein G agarose beads (cat. no. 15920-010; Life Technologies, Grand Island, NY, USA) were added for another 2-h incubation at 4°C. Proteins were loaded into sodium dodecyl sulphate polyacrylamide gel electrophoresis gels, transferred to a polyvinylidene difluoride membrane and blotted with primary and secondary antibodies.
Magnetic resonance imaging and magnetic transfer ratio acquisition and analysis
Acquisition of magnetic resonance imaging and magnetic transfer ratio (MTR) values of patients was carried out as described previously [7] .
Antibodies
Antibodies are listed in Table S1 .
Results
Patients present with an axonal polyneuropathy with no symptoms from the central nervous system or other organs
Clinical phenotypes Patient 0001. The proband is a 56-year-old man with a normal birth history. He was developmentally normal The remaining muscle groups in the legs and arms scored 5 on the MRC scale. Muscle atrophy was severe in distal legs but absent in hands and arms (Fig. 1c) . Sensation was intact to light touch, i.e. pinprick, decreased slightly at the toes and was normal at the ankles and knees. Deep tendon reflex was absent in ankle joints but present in other joints. His CMTES was 12. Patient 0100. The proband's brother is a 55-year-old man who had a normal birth/developmental history and excelled in track sports during his elementary school. He became symptomatic at 14 years of age and developed 'floppy' feet and calf muscle cramps. He tripped himself many times resulting in several ankle injuries. He uses a pair of high-edged boots to prevent future injury. He denied any sensory symptoms or history of diabetes, renal diseases or alcohol abuse. Neurological examination detected severe muscle weakness and atrophy in ankle dorsal/plantar flexors (0 on the MRC scale) but a score of 5 on the MRC scale in other muscles. Sensory examination was normal. Deep tendon reflex was absent in ankle joints but present in other joints. His CMTES was 6.
We evaluated his sister (0102) with neurological examination and NCS. The other sister (0101) and brother (0103) were not available for visit, but were interviewed over the phone and their DNA samples shipped. All three were found to be asymptomatic.
Electrophysiological findings
Two affected patients (0001 and 0100) were evaluated by NCS ( Table 2 ). The findings were consistent with a predominantly motor axonal polyneuropathy due to the following reasons. (i) Sensory nerve action potential in the legs was either normal or slightly decreased in amplitude in the two patients. Compound muscle action potential was absent in the legs but normal in the arms. In contrast, conduction velocities were normal or mildly reduced. (ii) Needle electromyography showed denervation in the distal leg muscles. No myopathic motor unit action potentials were observed. Note that the NCS was performed prior to the diagnosis of diabetes in the proband.
Magnetic resonance imaging findings in the proband's sciatic nerve and thigh muscles Physical findings in the patients suggested a lengthdependent process of the peripheral neuropathy ( Fig. 1c; Table 2 ). Although the distal motor nerves in the legs were severely affected and non-responsive in NCS, proximal nerves were difficult to evaluate by conventional NCS. We have established an MTR technique that can non-invasively quantify the proximal nerve pathology [7] . We studied the proband using this MTR technique (Fig. 2) . Again, this study was performed prior to his diagnosis of diabetes. As shown in Fig. 2c , his sciatic nerve diameter was below the range of normal controls. His MTR value was at the borderline of the lower limit of normal controls. Thigh muscle volumes on the cross-section appeared to be preserved. There might be subtle changes in the intramuscular architecture, which could be due to denervation. Together, these findings suggested an involvement of proximal nerves in the patient. As expected, the changes were mild in the proximal nerves, whereas the distal nerves were non-responsive in NCS. These features were in line with the lengthdependent process in axonal polyneuropathy. DNA analysis shows a missense mutation that changes a highly conserved phenylalanine to leucine in the first flavin adenine dinucleotide domain of apoptosis-inducing factor mitochondrion-associated-1
The proband's DNA was initially sequenced by targeted gene-panel next-generation sequencing, a commercial diagnostic service provided by Medical Neurogenetics. This technique was briefly described in the Materials and methods. This test identified a hemizygous missense mutation (c.630C>G) in AIFM1 on chromosome X. The mutation changed phenylalanine to leucine (Phe210Leu) in AIFM1. No mutation was found for the rest of the 42 CMT-related genes. In addition, whole mitochondrial DNA was sequenced and revealed no mutation. We verified the Phe210Leu missense mutation using Sanger sequencing in our laboratory (Fig. 3a) . Phe210Leu was only found in affected family members and was absent in non-affected family members (0102, 0103). Heterozygous Phe210Leu mutation was also found in subject 0101. She was asymptomatic for polyneuropathy but was considered as a carrier of the mutation. This co-segregation between Phe210Leu in AIFM1 and affected individuals supported its pathogenic role in this disease. Furthermore, phenylalanine at the 210 residue of AIFM1 is highly conserved across species (Fig. 3b) .
The mutation was evaluated by two servers, i.e. PolyPhen-2 and Sorts Intolerant From Tolerant (SIFT). Both predicted that Phe210Leu is damaging. In addition, the Phe210Leu allele was absent in 107 784 chromosomes of the control population in the Exome Aggregation Consortium (ExAC) database (http:// exac.broadinstitute.org/). Phe210Leu mutation misassembles mitochondrial complexes I and III in the absence of apoptosisinducing factor mitochondrion-associated-1 and MIA40 deficiency
To further evaluate the pathogenic role of the Phe210-Leu mutation, we tested whether the mutation aberrantly affected the assembly of mitochondrial complexes (CI-CV) as AIFM1 has been considered to be an assembly factor for mitochondrial complexes [4]. Lysates from human fibroblasts were analyzed by western blot, which showed that CI and CIII levels were decreased by approximately 80% when compared with controls (Fig. 4a) . Previous studies have demonstrated that deficiency of AIFM1 or MIA40 misassembles CI and CIV [4] . We thus evaluated levels of AIFM1 and MIA40 by western blot in human fibroblasts. The levels were similar in control and patient fibroblasts (Fig. 4a) .
Taken together, these data suggest that the Phe210-Leu mutation is sufficient to affect certain types of OXPHOS protein complexes independent of AIFM1/ MIA40 deficiency.
Interaction between apoptosis-inducing factor mitochondrion-associated-1 and MIA40 or between apoptosis-inducing factor mitochondrion-associated-1 and heat-shock protein-70 was not altered by the Phe210Leu mutation Apoptosis-inducing factor mitochondrion-associated-1 is also known to bind with MIA40. The Phe210Leu mutation could disrupt this protein-protein interaction that is important in the assembly of mitochondrial complexes [4] . We cultured fibroblasts from the skin biopsies taken from the two affected patients (0001, 0100), a sibling with no Phe210Leu mutation (0102) and a healthy, unrelated control. A co-immunoprecipitation experiment was performed with the protein extracts of these fibroblasts. This interaction was confirmed and was not altered in mutant cells (Fig. 4b) .
Heat-shock protein-70 is also known to bind AIFM1 at residues 150-288 in the cytosol. This interaction prevents the nuclear translocation of AIFM1, thereby inhibiting apoptosis [3] . The Phe210Leu mutation could also disrupt this protein-protein interaction. The co-immunoprecipitation experiment showed that the interaction between AIFM1 and heat-shock protein-70 was not changed in patients with the Phe210Leu mutation (Fig. 4b) .
Discussion
Our study has identified a family afflicted by an inherited axonal polyneuropathy with motor axons being predominantly damaged. This disease appears to be caused by a missense mutation (Phe210Leu) in AIFM1. This conclusion is supported by the following evidence. (i) The mutation was segregated in the affected individuals. (ii) A polyneuropathy has been reported in other families with mutations in AIFM1 (Table 1) , although additional tissues were also affected in those families. In some cases, motor axons were predominantly affected, which may have been called distal spinal muscular atrophy (Table 1 ) [8] . (iii) The Phe210Leu mutation changes a highly conserved amino acid. The mutation was not seen in the large cohort of the control population (ExAC database). (iv) Mutant AIFM1, not wild-type AIFM1, led the misassembly of CI and CIII.
Mutations in AIFM1 in previously reported families have resulted in diffuse pathologies in the nervous system and other organs, leading to severe neurological deficits in most cases (Table 1) . These may include mental retardation, abnormal cortical development of the cerebrum and myopathy. In contrast, the Phe210-Leu mutation in this family causes an isolated polyneuropathy with motor axons being predominantly affected. The patients had a late-onset, mild phenotype. The variable severities in all reported cases do not appear to have a clear association with mutations in specific domains of AIFM1 (Fig. 1) . For instance, Glu493Val mutation at the C-terminal results in a phenotype with earlier onset and more severe neuropathy (Table 1) than that in our cases with a missense mutation in the first flavin adenine dinucleotide domain, which has well-defined OXPHOS functions. However, severe phenotypes have been associated with significant reduction of AIFM1 and/or MIA40 protein levels in human cells and rodent models (Table S1 ). In contrast, the Phe210Leu mutation alters neither the levels of AIFM1 and MIA40 nor the binding between them. Together, these observations suggest that, whereas the Phe210Leu mutation is sufficient to cause the misassembly of CI and CIII, the preserved level of AIFM1 is still able to exert other functions, preventing our patients from displaying a severe phenotype. Certain pleiotropic functions of AIFM1 may not have been affected by the Phe210Leu mutation, but would be affected if AIFM1 was severely deficient.
It is still unclear how the Phe210Leu mutation misassembles CI and CIII. An elegant study has demonstrated that AIFM1 deficiency misassembles CI and CIV via its interaction with MIA40 and also results in MIA40 deficiency [4] . Because MIA40 is not deficient and binding between MIA40 and AIFM1 is still Figure 4 (a) Western blot analysis was performed in the fibroblasts of normal controls and patients with the Phe210-Leu mutation (0001 and 0100). Control 1 (49-year-old woman) was participant 0102 from this study. Control 2 was a 70-year-old man who was unrelated to this family. The percentages in parentheses are the ratios between patients and normal controls (normalized protein level in each patient:average of normalized protein levels from two normal controls). Western blot finding was replicated in a separate set of experiments. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was included as a loading control. Porin served as a control of mitochondrial volume. (b) Cell lysates were immunoprecipitated with anti-apoptosis-inducing factor mitochondrion-associated-1 (AIFM1) antibody and the precipitated endogenous proteins were blotted with anti-heatshock protein-70 (HSP70), anti-MIA40 and anti-AIFM1 antibody. IgG was used as negative control. b-Tubulin served as loading control. IP, Immunoprecipitation. preserved in Phe210Leu cells, the misassembly of CI/ CIII would not be achieved via the impaired interaction between AIFM1 and MIA40 or via MIA40 deficiency, but through a different mechanism. Therefore, the findings in our study may have made a conceptual advance. AIFM1/MIA40 deficiency is sufficient, but not necessary, to cause abnormal assembly of mitochondrial complexes. Certain mutations, such as Phe210Leu, are sufficient to misassemble mitochondrial complexes, independent of AIFM1/MIA40 deficiency. We speculate that this effect of Phe210Leu in the misassembly of OXPHOS complexes might be achieved by impaired interactions between AIFM1 and other unidentified proteins in the OXPHOS system. Alternatively, mutant AIFM1 may misassemble CI/CIII by blocking or impairing the function of MIA40, again independent of MIA40 deficiency.
It should be noted that each complex of CI-CV is comprised of multiple subunits. Our western blot (Fig. 4) only tested one subunit in each complex. Thus, the degree of reduction for the tested subunit does not necessarily reflect the degree of reduction of other subunits in the same complex. For this reason, other subunits in CIV could still be decreased in our patients.
Finally, our previous study demonstrated that noninvasive magnetic resonance imaging techniques can be used to define and quantify the pathological changes in myelin and axons of the peripheral nerves [7] . Although proximal nerves are difficult to access by NCS or biopsy, this problem can be circumvented by using magnetic resonance imaging. In this study, we were able to detect mild pathological changes in the proximal nerves.
In summary, we have identified a novel missense mutation in AIFM1 that probably causes X-linked CMT type 4 with isolated pathology in the motor neurons of the peripheral nerve system. With preserved levels of AIFM1/MIA40 and binding between AIFM1 and MIA40, the Phe210Leu mutation still results in misassembly of mitochondrial OXPHOS complexes. This observation reinforces the critical role of AIFM1 in the formation and/or maintenance of OXPHOS complexes.
